Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Sign Up to like & getrecommendations! Published in 2020 at "RMD Open"
DOI: 10.1136/rmdopen-2020-001217
Abstract: Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA). Methods This was a phase II, randomised, placebo-controlled, double-blind trial of adults… read more here.
Keywords: week; improvements enthesitis; dactylitis; enthesitis dactylitis ... See more keywords